Volitionrx Ltd (VNRX): Cameron John Reynolds , President and CEO of Volitionrx Ltd sold 3,390 shares on May 20, 2016. The Insider selling transaction was reported by the company on May 24, 2016 to the Securities and Exchange Commission. The shares were sold at $3.54 per share for a total value of $12,000.60 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2015, Cameron John Reynolds (CEO) purchased 1,500 shares at $3.37 per share price.On Feb 13, 2015, Guy Archibald Innes (director) purchased 50,000 shares at $3.75 per share price.
VolitionRX Ltd: On Friday, May 20, 2016 heightened volatility was witnessed in VolitionRX Ltd which led to swings in the share price. The shares opened for trading at $3.47 and hit $3.6 on the upside , eventually ending the session at $3.54, with a gain of 4.12% or 0.14 points. The heightened volatility saw the trading volume jump to 47,945 shares. The 52-week high of the share price is $5.25 and the company has a market cap of $83 M . The 52-week low of the share price is at $2.9.
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed 20 epigenetic NuQ assays using its Nucleosomics technology which is designed to detect the level and structure of nucleosomes in blood. The Company is developing two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; three blood assays in the NuQ-V family to detect cancer by detecting nucleosomes containing specific histone variants; nine blood assays in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones the proteins that package and order deoxyribo nucleic acid (DNA) into nucleosomes; five blood assays in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts and a NuQ-T assay to detect cancer by detecting total blood nucleosome levels.